Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A, Azzali I, Bittoni A, Marisi G, Rebuzzi F, Molinari C, Bartolini G, Matteucci L, Sullo FG, Debonis SA, Gallio C, Monti M, Valgiusti M, Muratore M, Rapposelli IG, Ulivi P, Frassineti GL. Passardi A, et al. Among authors: valgiusti m. Ther Adv Med Oncol. 2023 Dec 11;15:17588359231212184. doi: 10.1177/17588359231212184. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38107830 Free PMC article.
Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial.
Casadei Gardini A, Scarpi E, Valgiusti M, Monti M, Ruscelli S, Matteucci L, Bartolini G, Vertogen B, Pagan F, Rovesti G, Frassineti GL, Passardi A. Casadei Gardini A, et al. Among authors: valgiusti m. Ther Adv Med Oncol. 2020 Sep 28;12:1758835920958363. doi: 10.1177/1758835920958363. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33062063 Free PMC article.
Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial.
Passardi A, Rapposelli IG, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Avanzolini A, Cavaliere D, Rudnas B, Valgiusti M, Barone D, Ferroni F, Frassineti GL, Romeo A. Passardi A, et al. Among authors: valgiusti m. Ther Adv Med Oncol. 2020 Dec 8;12:1758835920977139. doi: 10.1177/1758835920977139. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33343722 Free PMC article.
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.
Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, Rosetti P, Bravaccini S, Calistri D, Saragoni L, Casadei Gardini A, Ragazzini A, Frassineti GL, Amadori D, Passardi A. Ulivi P, et al. Among authors: valgiusti m. J Transl Med. 2012 May 8;10:87. doi: 10.1186/1479-5876-10-87. J Transl Med. 2012. PMID: 22569004 Free PMC article.
Immune Checkpoints as a Target for Colorectal Cancer Treatment.
Passardi A, Canale M, Valgiusti M, Ulivi P. Passardi A, et al. Among authors: valgiusti m. Int J Mol Sci. 2017 Jun 21;18(6):1324. doi: 10.3390/ijms18061324. Int J Mol Sci. 2017. PMID: 28635639 Free PMC article. Review.
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.
Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D. Passardi A, et al. Among authors: valgiusti m. Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9. Sci Rep. 2017. PMID: 28874797 Free PMC article. Clinical Trial.
56 results